Dr. Salvador Eugenio C. Caoili, Dr. Ruby Anne N. King, Dr. Fresthel Monica M. Climacosa, Dr. Maria Isabel C. Idolor, Danica S. Ching
The invention provides anti-peptide immunoglobulins that recognize non-glycosylated epitopes of SARS-CoV-2 membrane glycoprotein, cognate oligopeptide-based immunogenic constructs suitable for producing said immunoglobulins, and methods for producing and utilizing said constructs and immunoglobulins.
- New materials for diagnostics
- For passive immunization to protect against and treat COVID-19
- Helps in the production of vaccines for active immunization against COVID-19
MARKET APPLICATIONS AND COMMERCIAL OPPORTUNITIES
In 2020, SARS-CoV-2 was declared by the World Health Organization as a global pandemic. Numerous kits have been commercialized in the market as rapid diagnostic tests (RDTs) and other systems for the detection of SARS-CoV-2 antigens and anti-SARS-CoV-2 antibodies. This technology aims to enable the development of such systems and other biomedical applications (e.g., vaccines and therapeutic antibodies) using low-cost materials to be manufactured in the Philippines and elsewhere.
The technology presented can be utilized in R&D and clinical/molecular diagnostic laboratories, as well as for the development of novel vaccines and therapeutics.
The technology is currently in the laboratory stage and needs further research and development.
Patent Application Filed
Application No. 1-2021-050256
TYPE OF PARTNERSHIP BEING SOUGHT
Licensing. Looking for partners or collaborators for clinical validation trials, licensees.